Patents by Inventor Glenn L. Stahl
Glenn L. Stahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090149431Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.Type: ApplicationFiled: February 18, 2009Publication date: June 11, 2009Inventors: Kathleen P. Barton, Thomas B. Borchardt, Marlow V. Carlos, Subhash Desai, Leonard J. Ferro, Henry T. Gaud, Scott S. Ganser, Clay R. Little, Partha S. Mudipalli, Mark A. Pietz, Daniel R. Pilipauskas, Yuen-Lung L. Sing, Glenn L. Stahl, Joseph J. Wieczorek, Chris Y. Yan
-
Publication number: 20050159594Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.Type: ApplicationFiled: July 16, 2004Publication date: July 21, 2005Applicant: Pharmacia CorporationInventors: Kathleen Barton, Thomas Borchardt, Marlon Carlos, Subhash Desai, Leonard Ferro, Henry Gaud, Scott Ganser, Clay Little, Partha Mudipalli, Mark Pietz, Daniel Pilipauskas, Yuen-Lung Sing, Glenn L. Stahl, Joseph Wieczorek, Chris Yan
-
Publication number: 20030083493Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.Type: ApplicationFiled: July 9, 2002Publication date: May 1, 2003Inventors: Kathleen P. Barton, Thomas B. Borchardt, Marlon V. Carlos, Subhash Desai, Leonard J. Ferro, Henry T. Gaud, Scott S. Ganser, Clay R. Little, Partha S. Mudipalli, Mark A. Pietz, Daniel R. Pilipauskas, Yuen-Lung L. Sing, Glenn L. Stahl, Joseph J. Wieczorek, Chris Y. Yan
-
Publication number: 20020045746Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.Type: ApplicationFiled: December 7, 2000Publication date: April 18, 2002Inventors: Kathleen P. Barton, Thomas B. Borchardt, Marlon V. Carlos, Subhash Desai, Leonard J. Ferro, Henry T. Gaud, Scott S. Ganser, Clay R. Little, Partha S. Mudipalli, Mark A. Pietz, Daniel R. Pilipauskas, Yuen-Lung L. Sing, Glenn L. Stahl, Joseph J. Wieczorek, Chris Y. Yan
-
Publication number: 20020038021Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.Type: ApplicationFiled: December 7, 2000Publication date: March 28, 2002Inventors: Kathleen P. Barton, Thomas B. Borchardt, Marlon V. Carlos, Subhash Desai, Leonard J. Ferro, Henry T. Gaud, Scott S. Ganser, Clay R. Little, Partha S. Mudipalli, Mark A. Pietz, Daniel R. Pilipauskas, Yuen-Lung L. Sing, Glenn L. Stahl, Joseph J. Wieczorek, Chris Y. Yan
-
Patent number: 5631399Abstract: The present invention relates to a novel process for the preparation of ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentyno ate and pharmaceutically acceptable acid addition salt thereof.Type: GrantFiled: May 14, 1996Date of Patent: May 20, 1997Assignee: G. D. Searle & Co.Inventors: Kevin A. Babiak, Srinivasan Babu, James R. Behling, Mark L. Boys, Kimberly J. Cain-Janicki, Wendel W. Doubleday, Payman Farid, Timothy J. Hagen, E. A. Hallinan, Donald W. Hansen, Jr., Donald E. Korte, Kathleen T. Mc Laughlin, John R. Medich, Sean T. Nugent, Vlasdislav Orlovski, Jung M. Park, Karen B. Peterson, Daniel R. Pilipauskas, Barnett S. Pitzele, Sofya Tsymbalov, Glenn L. Stahl
-
Patent number: 5536869Abstract: The present invention relates to a novel process for the preparation of ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentyno ate and pharmaceutically acceptable acid addition salt thereof which comprises treating (trimethylsilyl)acetylene sequentially with n-butyllithium and 4-formylmorpholine followed by acid hydrolysis to give 3-(trimethylsilyl)-2-propynal; treating 3-(trimethylsilyl)-2-propynal with lithium bis(trimethylsilyl)amide to give in situ N,3-bis(trimethylsilyl)-2-propyn-1-imine; condensation of N,3-bis(trimethylsilyl)-2-propyn-1-imine with lithium t-butyl acetate to give (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate; treating (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate- with p-toluenesulfonic acid to give (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate, mono p-toluenesulfonic acid salt, treatment of resulting salt with ethanol in the presence of p-toluenesulfonic acid to give (.+-.Type: GrantFiled: July 14, 1995Date of Patent: July 16, 1996Assignee: G. D. Searle & Co.Inventors: Kevin A. Babiak, Srinivasan Babu, James R. Behling, Mark L. Boys, Kimberly J. Cain-Janicki, Wendel W. Doubleday, Payman Farid, Timothy J. Hagen, E. Ann Hallinan, Donald W. Hansen, Jr., Donald E. Korte, Kathleen T. McLaughlin, John R. Medich, Sean T. Nugent, Vlasdislav Orlovski, Jung M. Park, Karen B. Peterson, Daniel R. Pilipauskas, Barnett S. Pitzele, Sofya Tsymbalov, Glenn L. Stahl
-
Patent number: 4824936Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have an alanine in position 19 instead of the natural leucine or phenylalanine found in those positions. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: May 6, 1987Date of Patent: April 25, 1989Assignee: Rorer Pharmaceutical CorporationInventors: Ronald C. Orlowski, Glenn L. Stahl, Robert L. Colescott
-
Patent number: 4659804Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a disulfide bond connecting the cysteines at positions one and seven. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin partially protected peptides.Type: GrantFiled: November 1, 1984Date of Patent: April 21, 1987Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Robert L. Colescott, Glenn L. Stahl, Takashi Enkoji, James E. Geever, Everett Flanigan
-
Patent number: 4639510Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have an S-acetamidomethyl cysteine at one and an alanine at seven, or an alanine at one and an S-acetamidomethyl cysteine at seven. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin-type peptides.Type: GrantFiled: October 4, 1985Date of Patent: January 27, 1987Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Glenn L. Stahl
-
Patent number: 4639509Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have an alanine in positions 16 and 19 instead of the natural leucine or phenylalanine found in those positions. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: March 28, 1985Date of Patent: January 27, 1987Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Glenn L. Stahl, Robert L. Colescott
-
Patent number: 4622386Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have cysteines at positions one and seven. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin-type peptides.Type: GrantFiled: March 28, 1985Date of Patent: November 11, 1986Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Glenn L. Stahl
-
Patent number: 4605515Abstract: New peptides ae disclosed which have biological activity of the same type as known calcitonins and contains only twenty-three amino acids rather than the normally occurring thirty-two amino acids. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: October 24, 1984Date of Patent: August 12, 1986Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Glenn L. Stahl
-
Patent number: 4605514Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a leucine in position 4. The position 4 leucine is omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: September 24, 1984Date of Patent: August 12, 1986Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Glenn L. Stahl
-
Patent number: 4604237Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a threonine in position 21. The position 21 threonine is omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: November 20, 1984Date of Patent: August 5, 1986Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Glenn L. Stahl
-
Patent number: 4604238Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have a shorter amino acid chain than natural calcitonins and are also substitution analogs of the natural calcitonins. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: December 10, 1984Date of Patent: August 5, 1986Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Glenn L. Stahl
-
Patent number: 4528132Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have an alanine in position 16 instead of the natural leucine or phenylalanine found in that position. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: January 13, 1984Date of Patent: July 9, 1985Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Glenn L. Stahl, Robert L. Colescott
-
Patent number: 4497732Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have a longer amino acid chain than natural calcitonins, specifically, the peptide chain of the disulfide ring is enlarged. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: October 21, 1983Date of Patent: February 5, 1985Assignee: Armour Pharmaceutical CompanyInventors: Jay K. Seyler, Glenn L. Stahl, Ronald C. Orlowski
-
Patent number: 4444681Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which are substitution analogs of natural calcitonins. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: September 24, 1982Date of Patent: April 24, 1984Assignee: Armour Pharmaceutical CompanyInventors: Glenn L. Stahl, Ronald C. Orlowski